Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: September 16, 2013
Reporting Period: This filing serves to incorporate by reference the company's unaudited interim consolidated financial statements for the period ended June 30, 2013, which were originally filed in Israel on August 29, 2013.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The actual financial statements (Exhibit 99.1) are referenced but not included in the input text. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes or comparative financial analysis are detailed in the provided text. The document solely announces the availability of the interim financial statements for the period ended June 30, 2013.
Guidance, Outlook, and Risks
The provided text contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. These details would be contained within the referenced Exhibit 99.1 (Unaudited Interim Consolidated Financial Statements).
Investor Verification Checklist
- Verify the specific financial figures (revenue, cash position, net loss) in the attached Exhibit 99.1, as they are not listed in this cover letter.
- Confirm the status of the company's clinical trials and product development pipeline, which are typically discussed in the full interim report.
- Review the liquidity position and cash burn rate detailed in the full financial statements to assess runway.
- Check for any subsequent events or updates between the June 30, 2013 reporting date and the September 16, 2013 filing date.